



India: Responsive COVID-19 Vaccines for Recovery Project under the Asia Pacific Vaccine Access Facility

Project Name	Responsive COVID-19 Vaccines for Recovery Project under the Asia Pacific Vaccine Access Facility	
Project Number	55082-001	
Country	India	
Project Status	Approved	
Project Type / Modality of Assistance	Loan	
Source of Funding / Amount	Loan 4147-IND: Responsive COVID-19 Vaccines for Recovery Project under the Asia Pacific Vaccine Access Facility	
	Ordinary capital resources	US\$ 1,500.00 million
	Loan 8408-IND: Responsive COVID-19 Vaccines for Recovery Project under the Asia Pacific Vaccine Access Facility	
	Asian Infrastructure Investment Bank	US\$ 500.00 million
Strategic Agendas	Environmentally sustainable growth Inclusive economic growth Regional integration	
Drivers of Change	Knowledge solutions Partnerships Private sector development	
Sector / Subsector	Health - Disease control of communicable disease	
Gender Equity and Mainstreaming	Effective gender mainstreaming	
Description	<p>The project will benefit significantly from an abbreviated consideration period by the Asian Development Bank (ADB) Board of Directors since it supports the Government of India's rapid vaccination rollout to contain the ongoing pandemic and the severity of a possible third wave as well as the loss of lives. The government has already placed orders for APVAX-eligible vaccines and incurred substantial costs from the accelerated pace of vaccination since August 2021. Timely ADB support would add value by helping meet urgent financing needs for delivering APVAX eligible vaccines for priority population, and allow government resources to procure the planned non-APVAX eligible vaccines. Vaccine financing would also safeguard essential expenditure on emergency response needs, strengthen the resilience of health systems, and contribute to the country's commitment to an earlier resumption of vaccine export.</p> <p>The project will provide the government with timely financing to procure safe and effective coronavirus disease (COVID-19) vaccines based on an agreed list of eligible expenditures under the rapid response component (RRC) of the Asia Pacific Vaccine Access Facility (APVAX). Ongoing technical assistance (TA) will complement the project by strengthening the vaccine delivery system.</p>	
Project Rationale and Linkage to Country/Regional Strategy	<p>Since the first case of COVID-19 was confirmed in India on 30 January 2020, another 33,236,920 cases were confirmed and 442,655 people have died from the virus as of 12 September 2021. The pandemic resulted in very high costs to the country's overall health, well-being, and economy. India faced a devastating second wave starting March 2021, which peaked with a record high of 414,188 new COVID-19 cases on 7 May 2021. This was about 32% higher than the world's previous peak reported by the United States in 2020. The second wave in India overwhelmed hospitals and exhausted health workers, who were increasingly becoming infected. Despite the containment measures with localized lockdowns and social distancing, increased testing capacity (more than 2.2 million samples per day) to detect and isolate cases, and a national vaccination drive, the possibility of a third wave looms large because of highly contagious variants.</p> <p>Equitable access to safe and effective vaccines is critical to ending the COVID-19 pandemic and has proven to be lifesaving. Recognizing this need, the government started rolling out inoculations on 16 January 2021. More than 738.2 million vaccine doses had been administered in more than 7.5 million sessions by 12 September 2021. India aims to inoculate 944.7 million people (68.9% of its total population). Given the devastating second wave and the possible threat of a third wave, the government allocated significant financing to health system strengthening efforts, which further strained its resource envelope. The government requires immediate financial support to procure eligible vaccines to inoculate its target population and limit the adverse impacts of the pandemic.</p>	
Impact	Accelerated health, social, and economic recovery from COVID-19 in India (NDVP for COVID-19 Vaccine)	
Project Outcome		
Description of Outcome	Eligible populations safely vaccinated against COVID-19 in project states	
Progress Toward Outcome		
Implementation Progress		
Description of Project Outputs	Safe and effective COVID-19 vaccines supplied for eligible population in project states	
Status of Implementation Progress (Outputs, Activities, and Issues)		
Geographical Location	Nation-wide, Andhra Pradesh, Assam, Bihar, Chhattisgarh, Delhi, Gujarat, Haryana, Jharkhand, Karnataka, Kerala, Madhya Pradesh, Maharashtra, Odisha, Punjab, Rajasthan, Tamil Nadu, Telangana, Uttar Pradesh, West Bengal	
Safeguard Categories		
Environment	C	
Involuntary Resettlement	C	

Summary of Environmental and Social Aspects	
Environmental Aspects	
Involuntary Resettlement	
Indigenous Peoples	
Stakeholder Communication, Participation, and Consultation	
During Project Design	
During Project Implementation	
Business Opportunities	
Procurement	Direct contracting
Responsible ADB Officer	Khetrupal, Sonalini
Responsible ADB Department	South Asia Department
Responsible ADB Division	Human and Social Development Division, SARD
Executing Agencies	Ministry of Health and Family Welfare 150 A Nirman Bhawan New Delhi - 110 011 India
Timetable	
Concept Clearance	01 Jan 2023
Fact Finding	11 Aug 2021 to 21 Sep 2021
MRM	28 Sep 2021
Approval	25 Nov 2021
Last Review Mission	-
Last PDS Update	25 Nov 2021

Loan 4147-IND

Financing Plan		Loan Utilization			
	Total (Amount in US\$ million)	Date	ADB	Others	Net Percentage
Project Cost	1,557.77	Cumulative Contract Awards			
ADB	1,500.00	-	0.00	0.00	%
Counterpart	57.77	Cumulative Disbursements			
Cofinancing	0.00	-	0.00	0.00	%

Loan 8408-IND

Financing Plan		Loan Utilization			
	Total (Amount in US\$ million)	Date	ADB	Others	Net Percentage
Project Cost	500.00	Cumulative Contract Awards			
ADB	0.00	-	0.00	0.00	%
Counterpart	0.00	Cumulative Disbursements			
Cofinancing	500.00	-	0.00	0.00	%

Project Page <https://www.adb.org/projects/55082-001/main>

Request for Information <http://www.adb.org/forms/request-information-form?subject=55082-001>

Date Generated 26 November 2021

ADB provides the information contained in this project data sheet (PDS) solely as a resource for its users without any form of assurance. Whilst ADB tries to provide high quality content, the information are provided "as is" without warranty of any kind, either express or implied, including without limitation warranties of merchantability, fitness for a particular purpose, and non-infringement. ADB specifically does not make any warranties or representations as to the accuracy or completeness of any such information.